(Q41262422)

28 September 2017

1 reference

title

Liposomal doxorubicin (English)

1 reference

28 September 2017

Tardi PG

1

1 reference

28 September 2017

Boman NL

series ordinal

2

1 reference

28 September 2017

Cullis PR

series ordinal

3

1 reference

28 September 2017

publication date

1 January 1996

1 reference

Journal of Drug Targeting

28 September 2017

published in

1 reference

28 September 2017

volume

4

1 reference

28 September 2017

issue

3

1 reference

28 September 2017

page(s)

129-140

1 reference

Liposome disposition in vivo. III. Dose and vesicle-size effects

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Liposomes with entrapped doxorubicin exhibit extended blood residence times

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Effects of liposome size on the degradation of bovine brain sphingomyelin/cholesterol liposomes in the mouse liver

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Liposomes for the sustained drug release in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

pH gradients and membrane transport in liposomal systems

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Invitro and invivo studies with adriamycin liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Determination of transmembrane pH gradients and membrane potentials in liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10611869609015970

10.3109/10611869609015970

21 January 2018

Identifiers

DOI

1 reference

28 September 2017

1 reference